Product

One permanent genome. A health record designed to grow.

The core is deliberately clear: full DNA for dogs and cats and a report that can be re-read. Additional layers enter only as their evidence and operating model are ready.

Founding programme

Aevum Pet

Core product
  • Target 30× whole-genome sequencing

    A home cheek swab or saliva sample is processed by a sequencing laboratory to create a full genomic baseline for a dog or cat.

  • Raw-data archive

    The underlying data is retained for portability and future reinterpretation, rather than reduced to a one-time breed or trait result.

  • Initial interpretation report

    Findings are prioritised, evidence-graded and written with explicit limits.

  • Genome reinterpretation

    Relevant new species-specific evidence can update the reading without resequencing the pet.

  • Longitudinal digital record

    New measurements and veterinary context can be brought into one traceable timeline.

No fixed price or launch configuration is being claimed while supplier, assay and regional decisions remain open.

Development roadmap

Promising does not mean ready

The blueprint includes recurring measurements, but each is labelled by its actual stage.

Research

Epigenetic / methylation age

Requires a species-specific assay with demonstrated validity and repeatability.

Phase 2

Veterinary blood biomarkers

Depends on standardised panels and country-specific veterinary workflows.

Partner evaluation

Continuous physiology

Integrate existing collar-device data before considering proprietary hardware.